CareTrack Aged: Appropriate Care Delivered To Australians Living In Residential Aged Care
Funder
National Health and Medical Research Council
Funding Amount
$1,157,722.00
Summary
Given Australia’s rapidly ageing population, keeping up with future demands and maintaining quality of care in residential aged care facilities (RACF) is vital. This study will assess whether care delivered is consistent with the evidence in 15 conditions that are frequently managed in RACFs. These will include delirium, dementia, depression, pain management and medication management. We will also assess the quality of life of residents in RACFs.
Evaluation Of SCID-I In The Diagnosis Of Mental Disorders In Indigenous Australians
Funder
National Health and Medical Research Council
Funding Amount
$988,007.00
Summary
Current estimates of mental disease among Indigenous Australians are inadequate. This research will examine the use of a structured interview tool that is promoted globally for diagnosing mental disorders, and then use the tool to quantify the burden of mental illness among Indigenous Australians. The findings will provide accurate estimates of occurrence of mental disorders, thereby help inform policy making and planning of services for Indigenous Australians.
ADding Negative PRESSure To Improve HealING (the DRESSING Trial)
Funder
National Health and Medical Research Council
Funding Amount
$2,380,446.00
Summary
The aim of this 5-year randomised comtrolled trial is to test the clinical and cost effectiveness of vacuum dressings in reducing the incidence of surgical site infection in obese women undergoing elective and semi-urgent caesarian section. The trial will be conducted at 4 hospitals in south east Queensland. 2,100 women undergoing caesarian section will either receive a vacuum or standard surgical dressing and will be followed for 1 month after surgery.
Which Heart Failure Intervention Is Most Cost Effective In Reducing Hospital Care (WHICH? II) Trial: A Multicentre, Randomised Trial Of Standard Versus Intensified Management Of Metropolitan And Regional-dwelling Patients With Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$1,891,210.00
Summary
Chronic heart failure (CHF) management programs are now the gold-standard to cost-effectively care for thousands of Australians hospitalised with CHF each year. We’ve shown that home-based management is most cost-effective in reducing hospital stay in CHF. The Which Intervention is most Cost-effective in reducing Hospital care (WHICH? II) Trial, a multicentre, randomised study, will determine if more intensive care (via home visits and remote care contacts) further improves poor outcomes in CHF.
Clinical And Psychosocial Changes Over Late Childhood And Adolescence And Early Life Determinants Of Long Term Clinical Outcomes In Cystic Fibrosis
Funder
National Health and Medical Research Council
Funding Amount
$1,135,570.00
Summary
Cystic fibrosis is the most common life shortening inherited disease in Caucasians. Lung damage starts in infancy and lung function falls most rapidly in adolescence although why and how this happens and early life determinants are not known. This study takes advantage of a previous study that monitored young children from 3 months to 5 years of life and follows them closely through early adolescence to investigate the protective and risk factors for falling lung function.
Probiotic Prawn Oral Immunotherapy (ProPIT) For Treatment Of Prawn Allergy
Funder
National Health and Medical Research Council
Funding Amount
$1,865,369.00
Summary
A ‘curative’ food allergy treatment is needed to prevent deaths and improve care. We recently showed that probiotic peanut oral immunotherapy (PPOIT) was highly effective for treating peanut allergy. 82% of PPOIT treated children gained tolerance compared to 4% of the placebo group. We will now test the combined probiotic-food OIT approach for treating prawn allergy. If successful, we will have identified the first treatment for prawn allergy and a platform treatment for other food allergies.
Improving Oesophageal Adenocarcinoma Outcomes Through Understanding Genomics And Treatment Toxicity.
Funder
National Health and Medical Research Council
Funding Amount
$1,013,282.00
Summary
Oesophageal adenocarcinoma is an aggressive cancer, as most patients will not survive for more than 5 years. Therefore we need to find better ways to treat patients. In this study we will identify the DNA mutations in oesophageal cancers that were part of clinical trial. The data allow us to determine why some tumours responded well to therapy, and why some patients had serious side effects to the treatment. The results will help inform on selection of therapy for future patients.
Harnessing Neuroplasticity To Improve Motor Performance In Infants With Cerebral Palsy: A Pragmatic Randomized Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$2,736,349.00
Summary
Every 15 hours an Australian baby is born with cerebral palsy. Despite confidence in early intervention, 50% don't receive intervention before their first birthday while awaiting diagnosis, and 8 of 10 previous trials have not produced any physical gains over and above natural development. We have promising data about a new brain training intervention that harnesses neuroplasticity and improves movement. Our trial will treat 300 infants with early training comparing results to Standard Care.
Neurobiology Of Childhood Speech Disorders: Improving Detection, Diagnosis And Clinical Care
Funder
National Health and Medical Research Council
Funding Amount
$994,575.00
Summary
One in 20 children have a speech disorder at school entry, with lifelong deficits in psychosocial, academic and employment outcomes. Little is known about the aetiology of speech disorders, preventing targeted care. We combine expertise in speech pathology, gene discovery and brain imaging, to advance knowledge on gene and brain contributions to speech disorder. We will have direct impacts on clinical care including detection, diagnosis and counselling, optimising outcomes for affected children.
Group A Streptococcal Human Challenge Study: Accelerating Vaccine Development
Funder
National Health and Medical Research Council
Funding Amount
$2,018,741.00
Summary
Infection with group A streptococcus (GAS) is a major cause of morbidity and mortality worldwide, including in the Aboriginal population of Australia. Concerted efforts for vaccine development have been hampered by the absence of a suitable animal model. To address this critical knowledge gap we propose to develop a controlled human infection model of GAS infection. This model will provide a direct pathway for the future appraisal of novel GAS vaccines.